Adult malignant hemangiopericytoma

Summary

Adult malignant hemangiopericytoma (MONDO:0003856) is a disease and 5 clinical trials. Top therapeutic interventions include pazopanib, ifosfamide, and romidepsin. A subtype of hemangiopericytoma, malignant — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	adult malignant hemangiopericytoma
Mondo ID	MONDO:0003856
DOID	DOID:6332
NCIT	C7946
UMLS	C0279547
MedGen	83522
GARD	0023697
Is cancer (heuristic)	no

Also known as: adult hemangiopericytoma, malignant · hemangiopericytoma, malignant of adults · malignant adult hemangiopericytoma

Disease family

This is a subtype of hemangiopericytoma, malignant. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › pericytic neoplasm › hemangiopericytic tumor › hemangiopericytoma › hemangiopericytoma, malignant › adult malignant hemangiopericytoma

Related subtypes (3): conventional malignant hemangiopericytoma, malignant mediastinum hemangiopericytoma, childhood malignant hemangiopericytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00346164	PHASE3	COMPLETED	Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
NCT00112463	PHASE2	COMPLETED	Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
NCT00492089	PHASE2	COMPLETED	Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
NCT01532687	PHASE2	COMPLETED	Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
NCT00720174	PHASE1	COMPLETED	Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PAZOPANIB	4	3
IFOSFAMIDE	4	1
ROMIDEPSIN	4	1
CIXUTUMUMAB	2	1
CHEMBL4066465	0	1
CHEMBL4068768	0	1
CHEMBL4171277	0	1